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Myotube cultures of the myogenic cell hne, C2, produce significantly lower levels of dystrophin than primary mouse cultures. We demonstrate 
that expression of the C2 dystrophin gene increases IO-fold in hybrid myotubes formed by fusion of C2 and dystrophin-deficient human myoblasts 
from a Duchenne muscular dystrophy patient. These results indicate that C2 cells are deficient in endogenous gene regulatory factors which enhance 
dystrophin expression, and that the C2 cell line may therefore be used to identify putative trans-acting factors involved in the regulation of 
dystrophin gene expression. 
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1. INTRODUCTION 
Dystrophin is a 427 kDa protein product of the 
Duchenne muscular dystrophy (DMD) gene [l]. It is 
expressed in a tissue-specific and developmentally regu- 
lated manner, being found most abundantly in termi- 
nally differentiated myogenic cells of all types [2]. 
A region 850 bp upstream of the cap site of the gene 
was initially shown to be capable of regulating muscle- 
specific transcription of a reporter gene in cell culture 
[3]. In particular a 96 bp sequence containing conserved 
CArG-box and E-box motifs was found to be sufficient 
to confer partial muscle specificity, but other potential 
positive and negative regulatory elements were detected 
upstream [4]. The CArG-box around position -91 bp 
has activating effects in muscle, cells and is clearly in- 
volved in regulation. No influence of MyoDl however, 
on the proximal E-box (-58 bp) was found, consistent 
with the pattern of expression of the DMD gene not 
only in skeletal muscle, but also in cardiac and smooth 
muscle where MyoDl has not been found [S-7]. 
An interesting observation made by Klamut et al. [3] 
was a deficiency in the expression of dystrophin mRNA, 
in myotube cultures of the murine myoblast cell line, 
C2, in comparison to cultures of primary myoblasts. 
The dystrophin promoter-reporter gene constructs, 
while being highly expressed in primary myotube cul- 
tures, were only very weakly active in C2 cultures. This 
suggests that deficiency of dystrophin expression by C2 
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cells may result from abnormal regulation of gene ex- 
pression. 
In this report we present evidence which shows that 
C2 myotube cultures do produce full-length dystrophin, 
but at levels which are lo-fold lower than those of pri- 
mary myotube cultures. Furthermore we show that the 
expression of the C2 dystrophin gene can be increased 
greatly in hybrid myotubes formed by co-fusion of C2 
and primary myoblasts. These results indicate that C2 
cells are deficient in trans-acting ene regulatory factors 
which have a positive effect on dystrophin expression. 
C2 cells exhibit normal regulated expression of both 
skeletal-actin [8] and creatine kinase genes [9], indicat- 
ing that other myogenic regulatory factors are generally 
present and functionally active. We therefore suggest 
that the C2 cell line can provide a model for the identi- 
fication of novel factors which influence dystrophin 
gene expression in a relatively specific manner. 
2. MATERIALS AND METHODS 
2.1. Preparation of muscle cultures 
Normal human and mouse myoblasts were obtained by primary 
enzymatic dissociation [lo] of limb muscle from human foetal abortis 
tissue, 1618 weeks gestation, and 3-week-old mice. Dystrophin-defi- 
cient primary human myoblasts were grown from a biopsy of a DMD 
patient, in which a dystrophin gene deletion spanning exons 49-50 had 
been demonstrated. C2C12 cells are a subclone of the C2 cell line 
isolated from normal mouse muscle [11,12]. Myoblasts were seeded at 
4 x lo4 cells/cm2 on collagen-coated plastic tissue culture dishes and 
glass coverslips. Cultures were allowed to proliferate in Ham’s FIO 
nutrient medium, with 15% v/v FCS, 2 mM glutamine, insulin at 100 
&ml, 1 PM dexamethasone, fibroblast growth factor and epidermal 
growth factor each at lO@ml. When confluent, cultures were trans- 
ferred into Dulbecco’s modified Eagles medium with 5% v/v heat- 
inactivated horse serum and 2 mM glutamine, to facilitate terminal 
differentiation. Hybrid myotube cultures were constructed by seeding 
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C2C12 cells (lO’/cm’) onto a confluent monolayer of human DMD 
myoblasts before transferring into differentiation medium. 
2.2. Immunocytochemistry and Western blot analysis 
Dystrophin expression in 14-day-old myotube cultures was exam- 
ined by immunocytochemical and Western blot analysis. Cells grown 
on coverslips were immunostained, as described by Dickson et al. [13] 
with a mouse monoclonal antibody to dystrophin called Mandys 1 
[14]. Human-mouse co-cultures were double-stained with Mandys 1 
and Hoechst dye #33258 [l l] to identify hybrid myotubes by differen- 
tial staining of human and mouse nuclei. Stained cells were viewed on 
a Zeiss microscope quipped with phase contrast and epifluorescence 
optics. For Western blot analysis myotube cultures on 100 mm plastic 
tissue culture dishes were harvested in 0.5 ml SDS-sample buffer, 
sonicated for 20 s and solubilised by heating at 100°C for 4 min. 
Equivalent aliquots were electrophoresed on 6% polyacrylamide mini- 
gels, blotted and probed with a mouse mononclonal antibody to 
dystrophin, 6D3 [15] as described previously [16]. Quantitative analy- 
sis of dystrophin bands revealed by Western analyses was performed 
by measuring absorption of white light on a Shimadazu scanning 
densitometer. 
3. RESULTS 
At the mRNA level previous studies have suggested 
abnormally low levels of dystrophin gene expression in 
C2 myotubes. To confirm this observation at the pro- 
tein level we used antibodies to dystrophin to perform 
immunofluoresence stains on C2 cultures. A positive 
control for dystrophin expression by murine myotubes 
in culture was provided by the staining of differentiated 
primary muscle cultures from a normal mouse. Anti- 
bodies to dystrophin produced a pattern of staining 
consistent with the localisation of this molecule to the 
myotube sarcolemma (Fig. 1A). No such staining was 
observed when these antibodies were used to examine 
differentiated C2 cultures (Fig. 1B). 
A co-culture of C2 and human DMD myoblasts was 
constructed to examine the possibility that dystrophin 
expression by C2 cells may be increased by co-fusion 
with other myoblasts, which are genetically deficient in 
dystrophin expression but may nevertheless provide 
factors which have a positive effect on dystrophin gene 
expression. 
Double staining of C2/human DMD myoblast co- 
cultures with Mandys 1 (anti-rod domain dystrophin) 
and Hoechst dye #33258, indicated that all hybrid 
myotubes, containing at least one nucleus from each 
species, stained positively for dystrophin (Fig. 2A-D). 
Within the same cultures, non-hybrid myotubes which 
contained nuclei from only one species did not stain for 
dystrophin (Fig. 2E-H). The pattern of staining in these 
hybrid myotubes was generally similar to that of normal 
human and mouse controls. However, several examples 
of hybrid myotubes were observed to exhibit discontin- 
uous patches of staining with dystrophin antibodies 
which, when compared to the Heochst dye stain, often 
corresponded closely to the location of C2 nuclei. 
Western blot analysis of dystrophin expression in the 
C2/human DMD myoblast co-cultures and appropriate 
control cultures, was performed (Fig. 3) to supplement 
the evidence provided by immunofluorescence staining. 
Western blots of differentiated C2 cultures, when 
probed with dystrophin antibodies (lane 4) revealed the 
presence of a faint protein band of 430 kDa. compara- 
ble in molecular weight to dystrophin in normal human 
(lane 1) and mouse (lane 5) primary cultures. This indi- 
cates that C2 cells can produce dystrophin, but at ex- 
tremely low levels in comparison to primary cultures. A 
second band of 180 kDa was also observed which was 
present (with lower intensity) in the mouse control, but 
not in the human control. This may be a proteolytic 
product of full-length dystrophin, or a protein product 
of murine myoblasts which has cross-reacting epitopes 
with dystrophin. 
A similar analysis of hybrid cultures (C2 and human 
DMD myoblasts) also revealed two protein bands of 
430 kDa and 180 kDa (Fig. 3, lane 3), but examination 
of Western blot autoradiographs by scanning densitom- 
etry (Table I) indicated that the quantity of protein in 
the 430 kDa band was almost lo-fold greater in hybrid 
cultures than in control C2 cultures. The level of dystro- 
phin expression in hybrid cultures, as examined by this 
method, was comparable to levels of dystrophin expres- 
sion in human and mouse primary cultures. As ex- 
Fig. 1. Immunostains of (A) primary mouse and (B) C2 muscle cultures with Mandys 1 monoclonal antibody to dystrophin, demonstrating a
deficiency of dystrophin expression in C2 myotubes. (Magnification x 800) 
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Fig. 2. Dual-immunostaining of differentiated C2/human DMD myoblast co-cultures with Mandys 1 antibody to dystrophin (A,C,E,G) and Hoechst 
dye #33258 (B,D,F,H). Hoechst dye produces a rough stain with murine nuclei (large arrows) anda smooth stain with human uclei (small rrows). 
Hybrid myotubes (A/B, C/D) demonstrate positive membrane staining for dystrophin, whereas no reactivity with Mandys 1 is apparent in 
non-hybrid myotubes containing either humanuclei only (E/F) or mouse nuclei only (G/H). (Magnification x 800) 
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Fig. 3. Western blot analysis of U/human DMD co-cultures and 
control cultures with a mono-clonal antibody to dystrophin, 6D3. 
Lanes 1 and 5 demonstrate l vels of full-length dystrophin expression 
m primary normal human and mouse cultures respectively. Ten-fold 
lower levels of full-length dystrophin are present in C2 cultures (lane 
4) and no dystrophin is apparent in human DMD cultures (lane 2). 
High levels of dystrophin expression, however, are evident in C2/ 
human DMD co-cultures, comparable to that expressed in primary 
human and mouse cultures. 
petted, no dystrophin was detected by Western blot 
analysis in control human DMD cultures (Fig. 3, lane 
2). 
4. DISCUSSION 
Klamut et al. [3] demonstrated a deficiency in the 
production of dystrophin mRNA in C2 cultures com- 
pared with that produced by primary myotube cultures. 
By Western blot analysis and scanning densitometry of 
autoradiographs we have established that myotube cul- 
tures of the C2 cell line do produce full-length dystro- 
phin, but at levels which are IO-fold lower than primary 
mouse and human cultures. These results suggest that 
C2 cells do have a functional dystrophin gene, but that 
they have a deficiency in the positive regulation of 
dystrophin gene transcription. Transcriptional control 
is established by the interaction of positive and negative 
regulatory trans-acting factors with cis-acting promoter 
and enhancer sequences [17]. 
Table I 
Quantitative analysis of dystrophin expression by scanning densito- 
metry of Western blot autoradiograph shown in Fig. 3 
Myotube culture Relative absorbance of the 430 kDa 
band 
Normal human 10.1 
Human DMD 0.0 
C2 x Human DMD 9.8 
c2 1.0 
Normal mouse 10.1 
In the present study we show that hybrid myotubes 
containing C2 and human DMD nuclei express high 
levels of dystrophin. Since the human DMD nuclei do 
not have a functional dystrophin gene, this result must 
represent a dramatic increase in expression of the C2 
dystrophin gene. In the same cultures non-hybrid 
myotubes did not immunostain for dystrophin, clearly 
indicating that enhanced dystrophin expression by C2 
nuclei was occuring as a direct result of the presence of 
human DMD nuclei within the same myotube. Human 
DMD nuclei therefore express trans-acting factors 
which can increase C2 dystrophin expression. These 
observations indicate that low levels of dystrophin 
mRNA and protein in C2 cells may result from a defi- 
ciency in the expression or activity of an endogenous 
mouse regulatory factor, which normally has a positive 
effect on dystrophin gene expression. When the missing 
factor was complemented by co-fusion with human 
DMD myoblasts, dystrophin expression by C2 nuclei 
increased almost IO-fold, to similar levels expressed in 
normal human and mouse cultures. 
The C2 cell line, in conjunction with genomic DNA 
transfection and expression studies, or by comparative 
protein binding (gel retardation) studies [181 may there- 
fore be used as a model for the characterisation of pos- 
itive trans-activating factors of the dystrophin gene. 
This approach may yield invaluable information about 
the regulation of dystrophin gene expression, which is 
currently poorly understood. It may also reveal novel 
gene regulatory factors with a central role in muscle 
differentiation. The deficiency of positive gene regula- 
tory factors in C2 cells also demonstrates the possibility 
that abnormal gene expression may be the result of 
abnormal gene regulatory mechanisms, rather than a 
defect of the gene itself. A minority of Duchenne and 
Becker muscular dystrophy patients for example pre- 
sent with very low expression levels of normal-sized 
dystrophin, but with no obvious abnormality of the 
dystrophin gene [ 191. Identification of putative gene reg- 
ulatory factors using the C2 cell line and examination 
of their expression in normal and dystrophic muscle 
may provide new evidence for the primary biochemical 
abnormalities in some muscular dystrophies. 
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